Observational studyLeukemia2025

A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents.

Rabia Shahswar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.